Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

9480	Companies
185517	Keywords
117903	Articles
99366	Press releases

Home
Companies
Moderna, Inc.

BRIEF

published on 03/26/2024 at 12:05, 1 year 8 months ago

Moderna Reports Positive Results in Phase 3 Trial of New COVID-19 Vaccine

Public Health COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283
PRESS RELEASE

published on 03/26/2024 at 12:00, 1 year 8 months ago

Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Moderna's mRNA-1283 shows higher immune response than mRNA-1273.222 in Phase 3 trial. Next-generation vaccine offers longer shelf life and storage benefits, paving way for flu-COVID combo vaccine, mRNA-1083

COVID-19 Vaccine Moderna Phase 3 Trial MRNA-1283 MRNA-1273.222
BRIEF

published on 02/29/2024 at 13:00, 1 year 9 months ago

Moderna Announces Fifth Annual Vaccine-Focused Investor Event

Investors Webcast Moderna Investor Event MRNA Vaccines
PRESS RELEASE

published on 02/29/2024 at 13:00, 1 year 9 months ago

Moderna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
Moderna, Inc. announces its fifth annual Investor Event focusing on vaccines and business updates on March 27, 2024. Presentation at 9:00 a.m. ET. Live webcast available on the Moderna website

Webcast MRNA Medicine Moderna Investor Event MRNA Vaccines
BRIEF

published on 02/28/2024 at 13:00, 1 year 9 months ago

Moderna announces participation in investor conferences

Investor Conferences Webcast MRNA Technology Moderna Health
PRESS RELEASE

published on 02/28/2024 at 13:00, 1 year 9 months ago

Moderna to Present at Upcoming Investor Conferences in March 2024
Moderna, Inc. to participate in upcoming investor conferences and showcase advancements in mRNA technology. Visit investors.modernatx.com for webcast details

Investor Conferences Healthcare Moderna Inc. MRNA Technology COVID-19 Vaccines
BRIEF

published on 02/22/2024 at 12:30, 1 year 9 months ago

Moderna announces mixed financial results for 2023 and optimistic outlook for 2024

2023 Financial Results 2024 Forecasts Moderna RSV Vaccine Research Pipeline
PRESS RELEASE

published on 02/22/2024 at 12:30, 1 year 9 months ago

Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
Moderna, Inc. reports Q4 revenues of $2.8 billion with a GAAP net income of $217 million. Expects regulatory approvals for RSV vaccine and forecasts 2024 product sales of $4 billion

Financial Results Moderna Inc. RSV Vaccine Product Sales Regulatory Approvals
PRESS RELEASE

published on 02/07/2024 at 06:00, 1 year 9 months ago

Moderna Chief Executive Officer Stéphane Bancel Elected to National Academy of Engineering
Moderna, Inc.'s CEO Stéphane Bancel elected to National Academy of Engineering for distinguished contributions to engineering and manufacturing of pharmaceutical products, including COVID-19 vaccine. Company has 45 mRNA therapeutic and vaccine programs in pipeline

Moderna Inc COVID-19 Vaccine Stéphane Bancel National Academy Of Engineering MRNA Technology
PRESS RELEASE

published on 02/01/2024 at 13:00, 1 year 10 months ago

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year

Financial Results Conference Call Moderna Inc Webcast MRNA Medicine

Accesswire

Published on 12/05/2025 at 18:00, 15 minutes ago

SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 17:15, 1 hour ago

TRX GOLD Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 17:00, 1 hour 15 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 2 hours 15 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 2 hours 30 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:51, 23 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 29 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:00, 1 hour 15 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 1 hour 50 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 2 hours 5 minutes ago

Reorganization of the Eckert & Ziegler Executive Board

Les Echos

Published on 12/05/2025 at 17:18, 57 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 3 hours 4 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 9 hours 30 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE